NIH R01 · 2024
CHI3L1-targeted small molecules for glioblastoma
PROJECT SUMMARY/ABSTRACT: Glioblastoma (GBM), the most common malignant primary brain tumor, is the most aggressive diffuse glioma of the astrocytic lineage. Despite recent advances in multimodality therapy for GBM incorporating surgery, radiotherapy, chemotherapy, and supportive care, the overall prognosis remains poor, and long-term survival is rare. Immunotherapy has the potential to harness the immune system to kill brain tumor cells; however, the outcome of ongoing clinical trials with immunotherapies for GBM has been unsatisfactory. The highly immunosuppressive nature of GBM represents a key resistance mechanism to immunotherapy as glioma cells escape effective antitumor immunity by…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.